June 28, 2017
Postmenopausal women with osteoporosis prescribed oral bisphosphonate therapy for at least 4 years were more likely to sustain a fracture if they had a lower bone material strength index score compared with women who did not sustain a fracture, according to findings from a Spanish study.
“Despite advantages and good adherence to therapy, some patients still experience fractures while receiving oral bisphosphonates,” Adolfo Diez-Perez, MD, PhD, of the Hospital del Mar Research Institute in Barcelona, Spain, and colleagues wrote. “Several factors may contribute to the apparent lack of full efficacy, such as low levels of vitamin D, concomitant diseases, very low bone mineral density and advanced deterioration of bone microarchitecture that induces a situation not fully compensated by the beneficial effects of drugs. Therefore, it would be interesting to explore whether bone characteristics at a tissue level can contribute to incident fractures in patients on active treatment.”